Ikọ-ẹjẹ (TB), ti o fa nipasẹ iko Mycobacterium(MTB), jẹ ewu ilera agbaye, ati ilosokeresistance si bọtiniTBAwọn oogun bii Rifampicinn (RIF) ati Isoniazid (INH)jẹ lominu ni bi awọnidiwo si agbayeTB Iṣakoso akitiyan.Dekun ati deedemolikula igbeyewoti TB ati resistance to RIF&INH jẹ iṣeduro nipasẹ WHO latida awọnawọn alaisan ti o ni arunasikoatipese wọn pẹlu itọju ti o yẹ ni akoko.
Awọn italaya
Ifoju 10.6 milionu eniyanṣaisan pẹlu TB ni ọdun 2022, Abajade ni ẹyaifoju 1.3 milionu iku, jina lati 2025 maili ti Ipari TB Strategy
TB-sooro oogun, paapaa MDR-TB (sooro si RIF&INH),ti wa ni increasingly ni ipa lori agbaye TB itọjuati idena.
Iyara igbakana TB ati RIF/INH ayẹwoni kiakia beere funsẹyìnatidiẹ munadoko itọju akawepẹluawọn abajade idanwo alailagbara oogun idaduro.
TiwaOjutu
Marco & Micro-igbeyewo káIwari TB 3-in-1 fun ikolu TB/RIF & Apo Iwari Atako NIHkí daradara okunfa tiTB ati RIF/INH ni ọkan erin.
Imọ-ẹrọ iṣipopada yo mọ wiwa nigbakanna ti TB ati MDR-TB.
3-in-1 TB/MDR-TB iwari ti npinnu ikolu TB ati awọn oogun laini akọkọ bọtini (RIF/INH) jẹ ki itọju TB akoko ati deede.
Ni aṣeyọri mọ idanwo TB mẹta (ikolu TB, RIF & NIH Resistance) ni wiwa kan!
Abajade iyara: Wa ni awọn wakati 2-2.5 pẹlu itumọ abajade adaṣe ti o dinku ikẹkọ imọ-ẹrọ fun iṣẹ ṣiṣe;
Apeere Idanwo: sputum, asa ri to, asa olomi
Ifamọ giga: 25 kokoro arun / mL fun TB, 200 kokoro arun / mL fun awọn kokoro arun RIF sooro, 400 kokoro arun / mL fun awọn kokoro arun INH, ni idaniloju idaniloju idaniloju paapaa ni awọn ẹru kokoro kekere.
Awọn ibi-afẹde pupọ: TB-IS6110; RIF-resistance-rpoB (507 ~ 503); INH-resistance-InhA, AhpC, katG 315;
Ifọwọsi Didara: Iṣakoso inu fun afọwọsi didara apẹẹrẹ lati dinku awọn odi eke;
Wide Compatibility: Ibamu pẹlu awọn ọna PCR akọkọ julọ fun iraye si laabu jakejado (Bio-Rad CFX96, SLAN-96P/96S, Bioer Quantgene 9600);
Ibamu Awọn Itọsọna WHO: Ni ibamu si awọn itọnisọna WHO fun iṣakoso ti iko-ara ti ko ni oogun, aridaju igbẹkẹle ati ibaramu ni iṣẹ iwosan.
Akoko ifiweranṣẹ: Jul-08-2024